TScan Therapeutics sets separation terms for outgoing CFO and CMO

TScan Therapeutics, Inc. filed a Form 8-K with the earliest reported event dated September 24, 2026, disclosing separation agreements for two departing executives. The filing follows an earlier Current Report from September 2, 2026, in which the company said that as part of a strategic reorganization, Jason A. Amello would step down as Chief Financial Officer and Chrystal Louis, M.D., MPH, would step down as Chief Medical Officer.¹

On September 24, 2026 and September 25, 2026 respectively, the company entered into separation agreements with Dr. Louis and Mr. Amello, under which each executive's employment ends on the earlier of November 1, 2026 or the date they begin other employment, consulting, or paid board service, with base salary and benefits continuing until then.¹

Mr. Amello retains his previously disclosed termination-related payments and benefits, and is eligible for a lump-sum cash award of $85,000 tied to achievement of a company milestone before his separation date, under the company's November 2025 retention program.¹

Dr. Louis similarly retains her previously disclosed termination-related payments and benefits, with eligibility for a $125,000 lump-sum cash award under the same 2025 retention program, contingent on the milestone being met before her separation date.¹

The company said full copies of the separation agreements will be filed as exhibits to its Form 10-Q for the quarter ending September 30, 2026.¹ The 8-K itself was signed and dated September 30, 2026 by Chief Executive Officer Gavin MacBeath, Ph.D.